SYRE
MaterialsSpyre Therapeutics Inc
$73.00+1.99 (+2.80%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SYRE Today?
No stock-specific AI insight has been generated for SYRE yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$6.1B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding86.3M
SYRE News
21 articles- Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive OfficerYahoo Finance·May 5, 2026
- Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·May 5, 2026
- Spyre Therapeutics Announces Grants of Inducement AwardsYahoo Finance·May 1, 2026
- Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseYahoo Finance·May 1, 2026
- Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?Yahoo Finance·Apr 30, 2026
- Spyre Therapeutics (SYRE): Favorite Stock of Elite Money ManagersYahoo Finance·Apr 27, 2026
- Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE)Yahoo Finance·Apr 23, 2026
- Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ PotentialYahoo Finance·Apr 20, 2026
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionYahoo Finance·Apr 16, 2026
- Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 DataYahoo Finance·Apr 16, 2026
- Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Investors Turn to Corporate EarningsYahoo Finance·Apr 15, 2026
- Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockGlobeNewswire Inc.·Apr 15, 2026
- Spyre (SYRE) Announces Stellar UC Treatment Trial, Hits 4-Year HighYahoo Finance·Apr 14, 2026
- Spyre Therapeutics Announces Proposed Public Offering of its Common StockBenzinga·Apr 13, 2026
- Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis ResultsYahoo Finance·Apr 13, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Apr 13, 2026
- Sector Update: Health Care Stocks Softer Monday AfternoonYahoo Finance·Apr 13, 2026
- Spyre stock soars as UC drug touts Entyvio-rivalling potentialClinicaltrialsarena·Apr 13, 2026
- Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as Trump Prepares to Block Strait of HormuzYahoo Finance·Apr 13, 2026
- Spyre drug for inflammatory bowel disease shows promise in early studyBiopharmadive·Apr 13, 2026
- Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsGlobeNewswire Inc.·Apr 13, 2026
All 21 articles loaded
Price Data
Open$70.68
Previous Close$71.01
Day High$73.51
Day Low$70.11
52 Week High—
52 Week Low—
Fundamentals
Market Cap$6.1B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding86.3M
About Spyre Therapeutics Inc
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
MaterialsPHARMACEUTICAL PREPARATIONS
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICPHARMACEUTICAL PREPARATIONS
CIK—
Composite FIGI—
Share Class FIGI—